Simon A Travers
Overview
Explore the profile of Simon A Travers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
243
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferreira R, Grant O, Moyo T, Dorfman J, Woods R, Travers S, et al.
Sci Rep
. 2018 Oct;
8(1):15031.
PMID: 30302011
The HIV-1 envelope (Env) glycoprotein is the primary target of the humoral immune response and a critical vaccine candidate. However, Env is densely glycosylated and thereby substantially protected from neutralisation....
2.
Moyo T, Ferreira R, Davids R, Sonday Z, Moore P, Travers S, et al.
Virology
. 2016 Nov;
501:12-24.
PMID: 27846415
Glycans on HIV-1 Envelope serve multiple functions including blocking epitopes from antibodies. We show that removal of glycan 301, a major target of anti-V3/glycan antibodies, has substantially different effects in...
3.
Jiang X, Feyertag F, Meehan C, McCormack G, Travers S, Craig C, et al.
J Virol
. 2015 Sep;
89(22):11457-72.
PMID: 26339063
Unlabelled: Entry inhibitors represent a potent class of antiretroviral drugs that target a host cell protein, CCR5, an HIV-1 entry coreceptor, and not viral protein. Lack of sensitivity can occur...
4.
Scheepers C, Shrestha R, Lambson B, Jackson K, Wright I, Naicker D, et al.
J Immunol
. 2015 Apr;
194(9):4371-8.
PMID: 25825450
The human Ig repertoire is vast, producing billions of unique Abs from a limited number of germline Ig genes. The IgH V region (IGHV) is central to Ag binding and...
5.
Kharsany A, Buthelezi T, Frohlich J, Yende-Zuma N, Samsunder N, Mahlase G, et al.
AIDS Res Hum Retroviruses
. 2014 Aug;
30(10):956-65.
PMID: 25077861
In South Africa, adolescents constitute a key population at high risk of HIV acquisition. However, little is known about HIV transmission among students within schools. This study was undertaken to...
6.
Seager I, Travers S, Leeson M, Crampin A, French N, Glynn J, et al.
AIDS Res Hum Retroviruses
. 2014 Jun;
30(10):975-83.
PMID: 24925099
There are few cohorts of individuals who have survived infection with HIV-1 for more than 20 years, reported and followed in the literature, and even fewer from Africa. Here we...
7.
Wright I, Travers S
Nucleic Acids Res
. 2014 May;
42(13):e106.
PMID: 24861618
The challenge presented by high-throughput sequencing necessitates the development of novel tools for accurate alignment of reads to reference sequences. Current approaches focus on using heuristics to map reads quickly...
8.
Shrestha R, Lubinsky B, Bansode V, Moinz M, McCormack G, Travers S
BMC Bioinformatics
. 2014 Feb;
15:33.
PMID: 24479419
Background: Many high throughput sequencing (HTS) approaches, such as the Roche/454 platform, produce sequences in which the quality of the sequence (as measured by a Phred-like quality scores) decreases linearly...
9.
Wood N, Fadda E, Davis R, Grant O, Martin J, Woods R, et al.
PLoS One
. 2013 Dec;
8(11):e80301.
PMID: 24303005
N-linked glycans attached to specific amino acids of the gp120 envelope trimer of a HIV virion can modulate the binding affinity of gp120 to CD4, influence coreceptor tropism, and play...
10.
Travers S
ISRN AIDS
. 2013 Sep;
2012:823605.
PMID: 24052884
The "glycan shield" exposed on the surface of the HIV-1 gp120 env glycoprotein has been previously proposed as a novel target for anti-HIV treatments. While such targeting of these glycans...